Goldman Sachs lowered the firm’s price target on Boston Scientific (BSX) to $93 from $98 but keeps a Buy rating on the shares. The firm is revising its base case model to reflect moderating assumptions on key end-market growth rates as well as taking a more risk-adjusted view of the company’s trajectory, the analyst tells investors in a research note. The catalyst path for Boston Scientific shares to see a sustained move higher includes positive read out from CHAMPION-AF and gaining constructive physician feedback as well as investors gaining conviction in diversification of growth drivers, the firm adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific added to ‘Tactical Outperform’ list at Evercore ISI
- Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
- Boston Scientific price target lowered to $90 from $110 at Stifel
- Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
- FDA inspectors found Boston Scientific pacemakers had battery issues, NYT says